CD151 expression is frequent but unrelated to clinical outcome in head and neck cancer.
Standard
CD151 expression is frequent but unrelated to clinical outcome in head and neck cancer. / Nienstedt, Julie Cläre; Gröbe, Alexander; Lebok, Patrick; Büscheck, Franziska; Clauditz, Till Sebastian; Simon, Ronald; Heumann, Asmus; Sauter, Guido; Möbius, Christoph; Münscher, Adrian; Knecht, Rainald; Blessmann, Marco; Heiland, Max; Pflug, Christina; kiehn, saskia.
in: CLIN ORAL INVEST, Jahrgang 21, Nr. 5, 06.2017, S. 1503-1508.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - CD151 expression is frequent but unrelated to clinical outcome in head and neck cancer.
AU - Nienstedt, Julie Cläre
AU - Gröbe, Alexander
AU - Lebok, Patrick
AU - Büscheck, Franziska
AU - Clauditz, Till Sebastian
AU - Simon, Ronald
AU - Heumann, Asmus
AU - Sauter, Guido
AU - Möbius, Christoph
AU - Münscher, Adrian
AU - Knecht, Rainald
AU - Blessmann, Marco
AU - Heiland, Max
AU - Pflug, Christina
AU - kiehn, saskia
PY - 2017/6
Y1 - 2017/6
N2 - ObjectivesCD151 is a plasma membrane protein belonging to the tetraspanin family. CD151 represents a putative therapeutic target and has been suggested as a prognostic marker in several cancer types. The present study aims to investigate the prognostic relevance of immunohistochemical CD151 expression in head and neck squamous cell carcinoma (HNSCC).Materials and methodsTissue microarray (TMA) sections containing samples from 667 cancers of oral cavity, oro- and hypopharynx and larynx, for which follow-up data were available, were analyzed for CD151 expression by immunohistochemistry.ResultsMembranous CD151 immunostaining was recorded in 269 (60.3 %) of 446 analyzable cases. Staining was considered weak in 129 (28.9 %), moderate in 98 (22.0 %), and strong in 42 (9.4 %) of cancers. CD151 expression was unrelated to histological grade, tumor stage, nodal status, or surgical margin. There was a tendency towards a somewhat lower prevalence of CD151 expression in tumors of the oral cavity (52.9 % positive) as compared to cancers of the oro-hypopharynx (62.1 %) and larynx (63.3 %; p = 0.0100). CD151 expression had no impact on patient survival.Clinical relevanceIn summary, immunohistochemical analysis of CD151 lacks prognostic utility in HNSCC. The high prevalence of CD151 expression in HNSCC emphasizes its putative relevance as a therapeutic target for further development of anti-CD151 drugs.
AB - ObjectivesCD151 is a plasma membrane protein belonging to the tetraspanin family. CD151 represents a putative therapeutic target and has been suggested as a prognostic marker in several cancer types. The present study aims to investigate the prognostic relevance of immunohistochemical CD151 expression in head and neck squamous cell carcinoma (HNSCC).Materials and methodsTissue microarray (TMA) sections containing samples from 667 cancers of oral cavity, oro- and hypopharynx and larynx, for which follow-up data were available, were analyzed for CD151 expression by immunohistochemistry.ResultsMembranous CD151 immunostaining was recorded in 269 (60.3 %) of 446 analyzable cases. Staining was considered weak in 129 (28.9 %), moderate in 98 (22.0 %), and strong in 42 (9.4 %) of cancers. CD151 expression was unrelated to histological grade, tumor stage, nodal status, or surgical margin. There was a tendency towards a somewhat lower prevalence of CD151 expression in tumors of the oral cavity (52.9 % positive) as compared to cancers of the oro-hypopharynx (62.1 %) and larynx (63.3 %; p = 0.0100). CD151 expression had no impact on patient survival.Clinical relevanceIn summary, immunohistochemical analysis of CD151 lacks prognostic utility in HNSCC. The high prevalence of CD151 expression in HNSCC emphasizes its putative relevance as a therapeutic target for further development of anti-CD151 drugs.
U2 - 10.1007/s00784-016-1911-3
DO - 10.1007/s00784-016-1911-3
M3 - SCORING: Journal article
C2 - 27444451
VL - 21
SP - 1503
EP - 1508
JO - CLIN ORAL INVEST
JF - CLIN ORAL INVEST
SN - 1432-6981
IS - 5
ER -